SCHEDULE: Vanguard Discloses 5% Stake in Omnicell

Vanguard Capital Management has reported beneficial ownership of 5% of Omnicell Inc.'s common stock as of March 31, 2026.

Summary

• Vanguard Capital Management, along with its affiliates, now beneficially owns 2,274,766 shares of Omnicell Inc. common stock.
• This holding represents 5% of the total class of securities.
• Vanguard Capital Management has sole voting power over 340,249 shares and sole dispositive power over 2,274,766 shares.
• The filing indicates that Vanguard funds and managed accounts have the right to receive dividends and proceeds from the sale of these securities, with no single other person holding more than a 5% interest.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing. It's a standard disclosure of institutional ownership and does not provide new operational or financial information about the company itself.

Positives

• Significant institutional ownership by a major asset manager like Vanguard can be seen as a positive signal of confidence in the company's long-term prospects.
• Vanguard's reporting of sole dispositive power over a substantial number of shares suggests active management and potential for continued investment.

Negatives

• The filing does not contain any negative financial or operational information about Omnicell; it solely reports Vanguard's ownership stake.

Risks

• While not explicitly stated as a risk in this filing, a large institutional holder like Vanguard could potentially influence corporate strategy or governance decisions, which may or may not align with all shareholder interests.

Future Outlook

This filing is a disclosure of ownership and does not contain forward-looking statements or guidance regarding Omnicell's future performance.

Industry Context

StockSavvy.ai notes that significant institutional filings like this Schedule 13G from major asset managers are common and reflect the ongoing investment landscape for publicly traded companies. Vanguard's substantial stake in Omnicell indicates its role as a key institutional investor in the healthcare technology sector.

Stakeholder Impact

• Shareholders: The filing confirms significant institutional interest from Vanguard, which may influence market perception and stock liquidity. It also clarifies that no single entity other than Vanguard (or its managed funds) holds over 5% of the shares, providing clarity on the shareholder base.
• Management and Employees: Continued institutional support can provide stability and confidence for management and employees.
• Creditors: Stable institutional ownership can be viewed positively by creditors as it may indicate a more stable corporate environment.

Next Steps

• Vanguard will continue to hold and potentially adjust its stake in Omnicell, subject to market conditions and investment strategies.
• Omnicell Inc. will continue its business operations as disclosed in its other SEC filings.

Key Dates

Keywords

Omnicell, Vanguard Capital Management, Schedule 13G, SEC Filing, Institutional Ownership, Common Stock, Beneficial Ownership, Investment Management